FDA Prescription Drug Labeling: The 201.56/201.57 Section Map

Prescription drug labeling in the United States is not free-form document design. Under the Physician Labeling Rule (PLR), 21 CFR 201.56 sets the content standard and 21 CFR 201.57 fixes the exact sections, in a mandatory order, that both the Highlights of Prescribing Information and the Full Prescribing Information must contain. If you are reviewing a label for completeness, drafting a new indication into an existing insert, or just trying to find where a given piece of safety information belongs, the regulation itself is the map — this page lays it out section by section.

What 21 CFR 201.56 Actually Requires

201.56(a) sets the substantive standard before any formatting rule applies: labeling must contain “a summary of the essential scientific information needed for the safe and effective use of the drug,” must be “informative and accurate and neither promotional in tone nor false or misleading,” and must be updated whenever new information makes existing labeling inaccurate, false, or misleading. Where feasible, labeling statements must be based on human data; where animal data is used to support a human safety statement, it has to be identified as animal data and presented alongside the human findings, not blended into it.

201.56(b) sets the scope — which products actually have to use the PLR format described below:

• Required: drugs approved on or after 30 June 2001 through 30 June 2006, any application still pending as of 30 June 2006, and any application submitted on or after 30 June 2006.
• Exempt from mandatory reformatting: drugs approved before 30 June 2001, which may continue to use the older labeling format described at 21 CFR 201.80. There is no blanket deadline forcing these older labels to convert — but a labeling change to one of them can trigger conversion, and FDA has pushed adoption further through labeling-change review over time.

This is the boundary that matters when you are asked to review or update a label: check the original approval date and format before assuming 201.57’s section list applies at all.

Highlights of Prescribing Information — 201.57(a), Required Order

Highlights is the condensed, front-of-insert summary. Its content must appear in this order, and by regulation the section (excluding the boxed warning) is meant to be brief enough to fit roughly half a printed page — it is a summary, not a second Full Prescribing Information:

1. Highlights limitation statement (the boilerplate noting Highlights does not include all information needed to prescribe safely and directing the reader to the Full Prescribing Information)
2. Drug name(s), dosage form, route of administration, and controlled-substance symbol if applicable
3. Initial U.S. approval year
4. Boxed warning, if the drug has one
5. Recent major changes
6. Indications and usage
7. Dosage and administration
8. Dosage forms and strengths
9. Contraindications
10. Warnings and precautions
11. Adverse reactions
12. Drug interactions
13. Use in specific populations
14. Patient counseling information statement (pointer to the Medication Guide/patient labeling if one exists)
15. Revision date

Full Prescribing Information — 201.57(c), Required Order

The regulation is explicit that this is a mandatory sequence: “the full prescribing information must contain the information in the order required under paragraphs (c)(1) through (c)(18).” A reviewer checking a label for completeness can walk this list top to bottom:

1. Boxed warning
2. Indications and usage
3. Dosage and administration
4. Dosage forms and strengths
5. Contraindications
6. Warnings and precautions
7. Adverse reactions
8. Drug interactions
9. Use in specific populations
10. Drug abuse and dependence
11. Overdosage
12. Description
13. Clinical pharmacology
14. Nonclinical toxicology
15. Clinical studies
16. References
17. How supplied/storage and handling
18. Patient counseling information

Notice the pattern: sections 1–9 of the Full Prescribing Information mirror the clinically-oriented sections of Highlights in the same order, which is deliberate — it lets a reader who wants more detail on, say, drug interactions jump to the matching numbered section in Full Prescribing Information without re-learning a different structure.

Why the Order Isn’t Optional

Because 201.57(c) fixes the order by regulation rather than leaving it to house style, a reviewer’s job is closer to conformance checking than free review: is a required section present, is it in the right numbered position, and does its heading match the regulation’s wording. This rigid, numbered structure is also exactly what makes prescription labeling machine-parseable — FDA requires labeling content to be submitted electronically as Structured Product Labeling (SPL), an XML format that encodes each of these numbered sections as a discrete, identifiable data element. If you also handle the electronic submission side of this same content, see CASRAI’s Structured Product Labeling (SPL) guide for the document types, data elements, and validation rules that apply once this section content is packaged for FDA and DailyMed.

Boxed Warning: Placement and Formatting

The boxed warning is the one piece of content that appears twice — as item 4 in Highlights and as item 1 in Full Prescribing Information — and it carries its own formatting rule on top of the ordering rule: it must be set off from the surrounding text (bordered box) and its heading must be in uppercase letters and contain the word “WARNING.” Reviewers checking an existing label for a boxed warning should confirm both placements are present and consistent with each other, not just that one of the two exists.

Using This as a Practical Review Checklist

For someone drafting or reviewing labeling content rather than just reading it, the numbered structure above maps directly onto common editorial tasks:

• Adding a new indication — goes into section 6 of Highlights and section 2 of Full Prescribing Information; check whether the change is significant enough to also require an update to the Highlights “Recent Major Changes” entry (section 5).
• A new contraindication or updated warning — sections 9–10 of Highlights, sections 5–6 of Full Prescribing Information; verify the same language (or a faithful summary, for Highlights) appears in both places.
• New clinical trial data supporting the label — section 15 of Full Prescribing Information (Clinical Studies), with any resulting change to Indications and Usage or Dosage and Administration propagated to both Highlights and Full Prescribing Information.
• A safety signal from post-market data — typically lands in Adverse Reactions (section 11 of Highlights, section 7 of Full Prescribing Information) or, if serious enough, escalates to a new or revised boxed warning.
• Revision date — the one Highlights field with no Full Prescribing Information counterpart; it should change on every substantive content revision, not just cosmetic edits.

How This Differs From Older-Format and OTC Labeling

Two adjacent labeling regimes are easy to confuse with the PLR format above and worth distinguishing explicitly:

• Pre-PLR prescription labeling (21 CFR 201.80) — the format used by drugs approved before 30 June 2001 that have not been required to convert. It does not use the Highlights/Full Prescribing Information split and does not follow the 201.57(c) numbered order.
• OTC Drug Facts labeling (21 CFR 201.66) — a separate, consumer-facing format for over-the-counter products, structured around a standardized “Drug Facts” panel rather than Highlights/Full Prescribing Information. It is a different regulation entirely, not a subset of 201.56/201.57.

If the product in front of you is prescription-only and was approved (or has pending applications) from mid-2001 onward, 201.56/201.57 is the governing structure; otherwise, confirm which of the two adjacent regimes actually applies before using this page’s section order as a checklist.

Frequently Asked Questions

Is the order of Full Prescribing Information sections actually mandatory, or just a strong convention?

Mandatory. 21 CFR 201.57(c) states directly that the full prescribing information must contain the required information in the order set out in paragraphs (c)(1) through (c)(18) — it is not a style guideline.

Do older, pre-2001 approved drugs ever have to convert to the PLR format?

Not on a blanket deadline. 201.56(b) exempts drugs approved before 30 June 2001 from mandatory reformatting, though FDA has continued to move older labels toward the PLR structure through the ordinary labeling-change review process over time.

How is this different from Structured Product Labeling (SPL)?

201.56/201.57 govern what content goes where in the human-readable label. SPL is the separate XML format FDA requires for submitting that same content electronically — see CASRAI’s SPL guide for the submission-side rules.

Does the boxed warning count as one of the 18 numbered Full Prescribing Information sections?

Yes — it is section 1 of Full Prescribing Information and also appears as item 4 of Highlights, with its own uppercase/boxed formatting requirement layered on top of the ordering rule.